Abilify
Product Images NDC 68151-4982

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Abilify (NDC 68151-4982). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Chemical Structure (Abilify Chemical Structure)

Chemical structure diagram of the active ingredient in ABILIFY, showing a dichlorophenyl group, a piperazine ring, and a ketone functional group.*

FDA Label Image

Figure 1 (Abilify Figure 1)

A chart titled 'Effect of Other Drugs on Abilify' depicting the pharmacokinetic impact of various drugs on aripiprazole levels. The horizontal axis shows the change relative to reference (without interacting drug) for AUC and Cmax parameters. The vertical axis lists interacting drugs categorized as CYP3A4 inhibitor, CYP2D6 inhibitor, CYP3A4 inducer, gastric acid blockers, and others, with plotted points and error bars representing fold changes and 90% confidence intervals.*

FDA Label Image

Figure 2 (Abilify Figure 2)

A scatter plot chart titled 'Effect of Other Drugs on Abilify' showing fold change and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax of dehydro-Aripiprazole with various drugs. The x-axis represents change relative to reference (without interacting drug) on a scale from 0.0 to 3.0, and the y-axis lists drug categories and inhibitors including CYP3A4 Inhibitor ketoconazole, CYP2D6 Inhibitor quinidine, CYP3A4 Inducer carbamazepine, gastric acid blockers famotidine, and others like valproate, lithium, and brazepam.*

FDA Label Image

Figure 3 (Abilify Figure 3)

A forest plot chart titled 'Effect of Abilify on Other Drugs' showing fold change and 90% confidence intervals for various drugs and enzymes. The horizontal axis represents the change relative to the reference without the interacting drug, ranging from 0.5 to 3.0. Drugs and enzymes listed include CYP2D6, CYP2C9, warfarin, omeprazole, amitriptyline, valproate, lithium, lorazepam, venlafaxine, and escitalopram, with data points displaying their pharmacokinetic parameters such as AUC and Cmax.*

FDA Label Image

Figure 4 (Abilify Figure 4)

A horizontal forest plot chart showing Aripiprazole fold change with 90% confidence interval across various special populations. The populations compared include poor vs. extensive CYP2D6 metabolizers, female vs. male gender, different age groups, and severity levels of hepatic and renal impairment. The x-axis represents change relative to reference, ranging from 0.5 to 3.0, with data points and error bars indicating variability in exposure (AUC and Cmax).*

FDA Label Image

Figure 5 (Abilify Figure 5)

A forest plot titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing pharmacokinetic comparisons for AUC and Cmax across various subgroups, including CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and renal impairment severity. The x-axis represents fold change relative to reference on a logarithmic scale from 0.5 to 3.0.*

FDA Label Image

Figure 6 (Abilify Figure 6)

A Kaplan-Meier curve graph showing the proportion of subjects with relapse over days from randomization for ABILIFY and placebo groups. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse. ABILIFY is shown with a solid blue line; placebo is shown with a dashed red line. A table below the x-axis lists the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 7 (Abilify Figure 7)

A line graph comparing the proportion of subjects with relapse over days from randomization between ABILIFY and placebo groups. The x-axis shows days from 0 to 182, and the y-axis shows the proportion with relapse ranging from 0 to 1. The ABILIFY group is represented by a solid blue line, and placebo by a dashed red line, with the placebo group showing a higher relapse proportion over time. Below the x-axis, a table lists the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 8 (Abilify Figure 8)

A Kaplan-Meier curve chart comparing ABILIFY and placebo effects over 364 days. The x-axis shows days from randomization, and the y-axis shows the proportion of subjects with relapse. ABILIFY is represented by a solid blue line, showing a lower relapse proportion compared to placebo's dashed red line. Below the x-axis, the number of subjects at risk for both groups is listed at multiple time points.*

FDA Label Image

Figure 9 (Abilify Figure 9)

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. It compares three groups: ARIP-LOW, ARIP-HIGH, and placebo, with separate lines indicating their mean score changes over time.*

FDA Label Image

Otsuka Logo (Abilify Otsuka Logo)

FDA Label Image

Label Image (Lbl681514982)

Label for ABILIFY 5 mg tablet showing the active ingredient aripiprazole. Manufactured by Otsuka Pharmaceutical, it includes lot number 4A83790 and an expiration date of 11/14. The label has a barcode and indicates prescription use only with product NDC 68151-4982.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.